A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1046-1054

  Ebert, Lisa M ^a   Yu, Chih Liu ^b   Clements, Craig S ^b   Robson, Neil C ^a   Jackson, Heather M ^a   Markby, Jessica L ^c   Dimopoulos, Nektaria ^a   Bee, Shin Tan ^a   Luescher, Immanuel F ^d   Davis, Ian D ^a   Rossjohn, Jamie ^b   Cebon, Jonathan ^a   Purcell, Anthony W ^c   Chen, Weisan ^a,e  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALANYLPROLYLARGINYLGLYCYLPROLYLHISTIDYLGLYCYLGLYCYLALANYLALANYLSERYLGLYCYLLEUCINE; AMINO ACID DERIVATIVE; CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA B7 ANTIGEN; ISCOMATRIX; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HLA-B ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 59149087069     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2926     Document Type: Article

References (43)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT. Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
2. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006;84:303-17.
3. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006;95:1-30.
4. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697-702.
5. Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005;105:2465-72.
6. Drane D, Gittleson C, Boyle J. Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007;6:761-72.
7. Chen Q, Jackson H, Parente P, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004;101:9363-8.
8. Shastri N, Schwab S. Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class i molecules. Ann Rev Immunol 2002;20:463-93.
9. Stoltze L, Schirle M, Schwarz G, et al. Two new proteases in the MHC class I processing pathway. Nat Immunol 2000;1:413-8.
10. Seifert U, Maranon C, Shmueli A, et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol 2003;4:375-9.
11. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002;419:480-3.
12. Melief CJ. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-54.
13. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol 1993;11:729-66.
14. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-14.
15. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 2006;27:11-6.
16. Probst-Kepper M, Stroobant V, Kridel R, et al. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med 2001;193:1189-98.
17. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 2001;14:81-92.
18. Miles JJ, Elhassen D, Borg NA, et al. CTL recognition of a bulged viral peptide involves biased TCR selection. J Immunol 2005;175:3826-34.
19. Probst-Kepper M, Hecht HJ, Herrmann H, et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. J Immunol 2004;173:5610-6.
20. Tynan FE, Borg NA, Miles JJ, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005;280:23900-9.
21. Wynn KK, Fulton Z, Cooper L, et al. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 2008;111:4283-92.
22. Guo H-C, Jardetzky TS, Garrettt TPJ, Lane WS, Strominger JL, Wiley DC. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 1992;360:364-6.
23. Green KJ, Miles JJ, Tellam J, van Zuylen WJ, Connolly G, Burrows SR. Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur J Immunol 2004;34:2510-9.
24. Tynan FE, Borg NA, Miles JJ, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I: Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005;280:23900-9.
25. Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006;95:203-47.
26. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 1999;82:442-8.
27. Benlalam H, Linard B, Guilloux Y, et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 2003;171:6283-9.
28. Corbiere V, Nicolay H, Russo V, et al. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Tissue Antigens 2004;63:453-7.
29. Jackson HM, Dimopoulos N, Chen Q, et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods 2004;291:51-62.
30. Macdonald WA, Purcell AW, Mifsud NA, et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 2003;198:679-91.
31. The CCP4 suite: programs for protein crystallography. Acta Crystallogr 1994;50:760-3.
32. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr 2005;61:458-64.
33. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr 2004;60:2126-32.
34. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Ann Rev Immunol 1997;15:749-95.
35. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
36. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
37. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev 2006;6:883-94.
38. Gras S, Kjer-Nielsen L, Burrows SR, McCluskey J, Rossjohn J. T-cell receptor bias and immunity. Curr Opin Immunol 2008;20:119-25.
39. Godfrey DI, Rossjohn J, McCluskey J. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Immunity 2008;28:304-14.
40. Tynan FE, Burrows SR, Buckle AM, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 2005;6:1114-22.
41. Tynan FE, Reid HH, Kjer-Nielsen L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007;8:268-76.
42. Clements CS, Dunstone MA, Macdonald WA, McCluskey J, Rossjohn J. Specificity on a knife-edge: the αβ T cell receptor. Curr Opin Struct Biol 2006;16:787-95.
43. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005;207:145-57.